Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.66 |
| ▸ | RXRB | P28702 | 1/20 | 0.66 |
| ▸ | RXRG | P48443 | 1/20 | 0.66 |
| ▸ | PTPN5 | P54829 | 4/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethane SCHEMBL6908245 | 0.97 | RXRA (0.63) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL5352034 | 0.97 | RXRA (0.62) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL611807 | 0.95 | RXRA (0.67) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL29681626 | 0.95 | RXRA (0.67) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL14188565 | 0.93 | RXRA (0.65) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL5355878 | 0.93 | RXRA (0.65) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL29727265 | 0.93 | RXRA (0.65) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL8676319 | 0.90 | RXRA (0.56) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL13533360 | 0.87 | RXRA (0.59) | RXRARXRBRXRGPTPN5HDAC4 | |
| SCHEMBL22888510 | 0.87 | RXRA (0.59) | RXRARXRBRXRGPTPN5HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9077694-A | — | — | None | — | — | JP | disclosed |
| CN-110041246-A | The synthesis and application of novel Kessazulen sesquiterpene alkaloids | 中国海洋大学 | 2019-07-23 | — | — | CN | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-7105527-B2 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2006-09-12 | — | — | US | disclosed |
| EP-1461041-A4 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD (BB) | 2006-03-29 | — | — | EP | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| JP-H0977694-A | NEW PRODUCTION OF GUAIAZULENE OR ITS DERIVATIVE | TAKASAGO INTERNATL CORP | 1997-03-25 | — | — | JP | disclosed |
| US-4912134-A | Methyl ester substitution | AJINOMOTO COMPANY, INC. (JP) | 1990-03-27 | — | — | US | disclosed |
| US-4859701-A | Azulene derivatives and pharmaceutical compositions containing them | AJINOMOTO CO., INC. (JP) | 1989-08-22 | — | — | US | disclosed |
| EP-0266956-A2 | Azulene derivatives and pharmaceutical compositions containing them | AJINOMOTO CO., INC. (JP) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | RXRA 3754/4885RXRB 3661/4885RXRG 3571/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | RXRA 4461/4885RXRB 4393/4885RXRG 4336/4885 |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | RXRA 1748/4885RXRB 1804/4885RXRG 2192/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | RXRA 3672/4885RXRB 4331/4885RXRG 4424/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | RXRA 3747/4885RXRB 3661/4885RXRG 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.